Scancell approved to raise dose on cancer vaccine trials

AIM-listed Scancell, the developer of therapeutic cancer vaccines, has announced that two key medical regulation bodies have given approval for a higher dose to be allowed in the company's latest trials on a vaccine to treat melanoma.

AIM-listed Scancell, the developer of therapeutic cancer vaccines, has announced that two key medical regulation bodies have given approval for a higher dose to be allowed in the company's latest trials on a vaccine to treat melanoma.

The Gene Therapy Advisory Committee and the Medicines and Healthcare Products Regulatory Agency's (MHRA) Medicines Division gave their approval for Scancell to dose an extra group of patients with a higher, 8 mg, dose of SCIB1, its DNA ImmunoBody vaccine being developed for the treatment of melanoma.

Subscribe to MoneyWeek

Become a smarter, better informed investor with MoneyWeek.

Scancell is planning to start treating patients with the 8mg dose in the new year.

This update follows the announcement made by Scancell on December 6th 2012, of preliminary results from Part 1 of the Phase 1/2 clinical trial of SCIB1 in patients with Stage III/IV malignant melanoma.

Advertisement
Advertisement - Article continues below

In view of the encouraging results and minimal side effects seen with the 4mg dose, the company stated that it intended to evaluate an 8mg dose in parallel with Part 2 of the Phase1/2 study.

Part 2 of the study continues to be on track to be completed by the end of 2013. A successful outcome, if achieved, would confirm the potential of SCIB1 as a new cancer treatment as well as validating the Immunobody platform technology.

Professor Lindy Durrant, Joint Chief Executive Officer of Scancell, commented: "This approval from GTAC and MHRA provides Scancell with the opportunity to determine whether a higher dose of SCIB1 would be even more effective in inducing immune response and clinical benefit in late stage melanoma patients."

Scancell's share price was up 2.06% to 49.50p at 12:26 on Wednesday afternoon.

MF

Advertisement

Recommended

Visit/investments/investment-strategy/600861/how-demographics-affects-stock-valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Visit/investments/stocks-and-shares/600863/sirius-minerals-anglo-american-takeover
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Visit/investments/stockmarkets/600634/why-investors-should-be-cautiously-bullish-for-2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020
Visit/investments/stocks-and-shares/share-tips/600636/class-acts-going-cheap-buy-into-europes-best
Share tips

Class acts going cheap: buy into Europe’s best bargains

Value investing appears to be making a comeback, while shares on this side of the Atlantic are more appealing on metrics such as price/earnings ratios…
16 Jan 2020

Most Popular

Visit/investments/stockmarkets/601028/stockmarket-crash-more-to-come
Stockmarkets

Stockmarket crash: more to come

The stockmarket crash was hard and sudden – and it might not be over yet. But while the short term outlook is awful, says Merryn Somerset Webb, that d…
23 Mar 2020
Visit/investments/stockmarkets/601030/markets-are-starting-to-realise-just-how-bad-the-coronavirus-crisis
Stockmarkets

Markets are starting to realise just how bad the coronavirus crisis will be

As governments around the world throw everything including the kitchen sink in the fight against coronavirus, markets are reaching the “moment of maxi…
23 Mar 2020
Visit/trading/601011/international-consolidated-airlines-a-buy-for-the-brave
Trading

International Consolidated Airlines: a buy for the brave

International Consolidated Airlines, BA’s parent company, is dirt cheap and well placed to recover. Here's how to play it.
23 Mar 2020
Visit/investments/commodities/600729/the-rare-earth-metal-that-wont-be-a-secret-for-long
Sponsored

The rare earth metal that won't be a secret for long

SPONSORED CONTENT – You can’t keep a good thing hidden forever; now is the time to consider Pensana Rare Earths and the rare earth metals NdPr.
31 Jan 2020